Table 2. Comparison of afatinib dose and effects according to brain metastases.
| Variable | Patients with afatinib as first-line treatment | P-value | ||
|---|---|---|---|---|
| All | With BM | Without BM | ||
| (n = 259) | (n = 82) | (n = 177) | ||
| Initial dose with 40 mg, n (%) | 181 (69.9) | 58 (70.7) | 123 (69.5) | 0.84 |
| 40 mg in the first 6 months, n (%) | 139 (53.7) | 45 (54.9) | 94 (53.1) | 0.79 |
| Initial tumor response to afatinib treatment, n (%) | 0.211 | |||
| PR | 180 (69.5) | 52 (63.4) | 128 (72.3) | |
| SD | 60 (23.2) | 21 (25.6) | 39 (22.0) | |
| PD | 19 (7.3) | 9 (11.0) | 10 (5.6) | |
| Disease progression events after treatment, n | 148 (57.1) | 54 (65.9) | 94 (53.1) | 0.054 |
| CNS progression, n (%) | 47 (18.1) | 27 (32.9) | 20 (11.3) | <0.001* |
| Non-CNS progression, n (%) | 101 (39.0) | 27 (32.9) | 74 (41.8) | |
BM, brain metastases; CNS, central nervous system; PD, progressive disease; PR, partial response; SD, stable disease.